Shire ‘pleased with ADHD drug results’

Shire has reported that it is pleased with the results of studies assessing the efficacy of Vyvanse (lisdexamfetamine dimesylate) as a treatment for attention deficit hyperactivity disorder (ADHD) in adults, with the firm contending that the compound will meet an area of unmet medical need for adult ADHD treatment.

The company expressed plans to announce full results from phase III clinical trials investigating the use of the compound to treat adults with ADHD at a significant scientific conference in the fourth quarter of this year.

Vyvanse is a prodrug stimulant that is inactive in the human body until it is metabolised, after which it releases active d-amphetamine.

The compound is different from similar orally-administered long-acting stimulants that are dependent upon delivery systems potentially affected by gastrointestinal and pH transit time.

The drug is currently approved by the US Food and Drug Administration for the treatment of ADHD in children, while the company has submitted a supplemental New Drug Application for its use in adults.

Matthew Emmens, chief executive officer of Shire, said: “ADHD is a treatable disorder that affects adults as well as children.

“We are pleased with the results of Vyvanse studies conducted in adults and we believe this product will meet an important need in the adult ADHD marketplace.”

He added that the compound holds a key position on the company’s portfolio of ADHD treatments, with the company dedicated to the development of the drug as a treatment for adults suffering from ADHD.

In February 2007, Shire announced the acquisition of New River Pharmaceuticals, a transaction designed to facilitate the capturing of the “full economic value” of Vyvanse.